| P50 | author | Robin Murray | Q7352679 |
| P2093 | author name string | Marta Di Forti | |
| | Paul D Morrison | |
| | Alessandra Paparelli | |
| P2860 | cites work | ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE | Q22242795 |
| | Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects | Q22248075 |
| | Hallucinogens | Q22251224 |
| | What causes the onset of psychosis? | Q22251464 |
| | Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology | Q24602238 |
| | The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin | Q24643876 |
| | High-potency cannabis and the risk of psychosis | Q24651025 |
| | Role of endogenous cannabinoids in synaptic signaling | Q28185075 |
| | Gene-environment interactions in mental disorders. | Q28236145 |
| | The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus | Q46737888 |
| | Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology | Q46750655 |
| | The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization | Q46910414 |
| | The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats | Q46937520 |
| | Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants | Q48124141 |
| | Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 |
| | Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. | Q48217968 |
| | Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics | Q48269596 |
| | Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults | Q48287666 |
| | Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice | Q48477201 |
| | Amphetamine psychosis: behavioral and biochemical aspects | Q48597445 |
| | Alterations in the cortical serotonergic system in schizophrenia: a postmortem study | Q48622012 |
| | Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis | Q48723515 |
| | Different effects of nabilone and cannabidiol on binocular depth inversion in Man. | Q51080370 |
| | The environment and schizophrenia: the role of cannabis use. | Q51928698 |
| | Cannabis dependence and psychotic symptoms in young people | Q52024293 |
| | Model psychoses and schizophrenia | Q52139726 |
| | Intravenous nonbarbiturate, nonnarcotic analgesics: preliminary studies. 1. Cyclohexylamines. | Q52770004 |
| | Sernyl (CI-395) in clinical anaesthesia. | Q52770612 |
| | Study of a new schizophrenomimetic drug; sernyl. | Q52771570 |
| | A study of a 1-aryl cyclo hexyl amine for anesthesia. | Q52772312 |
| | Substance use in a population-based clinic sample of people with first-episode psychosis | Q57773718 |
| | Cannabis and psychosis | Q59187306 |
| | Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients | Q68310985 |
| | Effects of cannabidiol in animal models predictive of antipsychotic activity | Q68312624 |
| | Hallucinogenic drugs as precipitants of schizophrenia | Q68823678 |
| | Studies of drug-free schizophrenics and controls | Q69020085 |
| | Elevated endogenous cannabinoids in schizophrenia | Q73029596 |
| | Some serotoninlike activities of lysergic acid diethylamide | Q74117696 |
| | Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man | Q77339856 |
| | Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception | Q78888104 |
| | Schizophrenia therapy: beyond atypical antipsychotics | Q81286910 |
| | Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review | Q28238516 |
| | Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 |
| | Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial | Q28244389 |
| | Cannabis and schizophrenia. A longitudinal study of Swedish conscripts | Q28283322 |
| | Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics | Q28575182 |
| | Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia | Q29364524 |
| | Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 |
| | Recent advances in the phencyclidine model of schizophrenia | Q29618917 |
| | The role of the basal ganglia in habit formation | Q29619829 |
| | The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis | Q30047193 |
| | Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction | Q30053550 |
| | The role of serotonin in antipsychotic drug action | Q33702888 |
| | The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine | Q33808892 |
| | Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans | Q33886277 |
| | Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study | Q33962711 |
| | Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens | Q34032832 |
| | Dimethyltryptamin: its metabolism in man; the relation to its psychotic effect to the serotonin metabolism | Q34240334 |
| | Tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine | Q34240688 |
| | Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects | Q34253509 |
| | The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate | Q34255204 |
| | Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice | Q34438163 |
| | Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action | Q34485906 |
| | EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. | Q34540614 |
| | History of cannabis as a medicine: a review | Q34543279 |
| | Provocative tests with psychostimulant drugs in schizophrenia | Q34559517 |
| | Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. | Q34587365 |
| | Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling | Q34650334 |
| | Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia | Q34707093 |
| | LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry | Q34713743 |
| | Schizophrenia: from developmental deviance to dopamine dysregulation | Q34781344 |
| | Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology | Q34783101 |
| | Cannabidiol for the treatment of psychosis in Parkinson's disease | Q34830827 |
| | Psychedelics and schizophrenia | Q34958504 |
| | Can recreational doses of THC produce significant dopamine release in the human striatum? | Q34987781 |
| | Neuromechanism of developing methamphetamine psychosis: a neuroimaging study | Q45150004 |
| | Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. | Q45163158 |
| | Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization | Q45168618 |
| | Amphetamine poisoning. Effectiveness of chlorpromazine | Q45177562 |
| | The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning | Q46066974 |
| | The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms? | Q46072268 |
| | Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. | Q46279749 |
| | Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. | Q46359391 |
| | Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum | Q46406572 |
| | Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice | Q46445634 |
| | Half a century of antipsychotics and still a central role for dopamine D2 receptors | Q35595235 |
| | Phenotype of schizophrenia: a review and formulation | Q35875976 |
| | Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method | Q36050571 |
| | Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. | Q36119168 |
| | Cannabis use and misuse prevalence among people with psychosis | Q36274751 |
| | The basal ganglia: learning new tricks and loving it. | Q36306845 |
| | Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. | Q36452302 |
| | Endocannabinoid-mediated synaptic plasticity in the CNS. | Q36507561 |
| | Action selection and refinement in subcortical loops through basal ganglia and cerebellum | Q36737952 |
| | Risk factors for schizophrenia--all roads lead to dopamine | Q36751054 |
| | Dopamine-mediated regulation of corticostriatal synaptic plasticity. | Q36762821 |
| | Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? | Q36784126 |
| | Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity | Q37140712 |
| | What we know: findings that every theory of schizophrenia should explain. | Q37159625 |
| | Striatal plasticity and basal ganglia circuit function | Q37336143 |
| | Psychological effects of ketamine in healthy volunteers. Phenomenological study | Q37338708 |
| | Prevalence of psychotic symptoms in substance users: a comparison across substances | Q37346851 |
| | Genetic association studies of methamphetamine use disorders: A systematic review and synthesis | Q37394034 |
| | Human hallucinogenic drug research in the United States: a present-day case history and review of the process | Q37469189 |
| | Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature | Q37672831 |
| | Dopaminergic mechanisms in idiopathic and drug-induced psychoses | Q37920162 |
| | Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study | Q39680990 |
| | Catecholamines in the brain as mediators of amphetamine psychosis | Q39895896 |
| | Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents | Q40156156 |
| | Increased excretion of dimethyltryptamine and certain features of psychosis: a possible association | Q40595117 |
| | Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide | Q41355565 |
| | Dopaminergic sensitization: implications for the pathogenesis of schizophrenia | Q41389291 |
| | A two-process theory of schizophrenia: evidence from studies in post-mortem brain | Q41581748 |
| | Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Serotonergic basis of antipsychotic drug effects in schizophrenia. | Q42537934 |
| | Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge | Q43069548 |
| | Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers | Q43235412 |
| | Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. | Q43570628 |
| | Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans | Q43842099 |
| | Postsynaptic endocannabinoid release is critical to long-term depression in the striatum | Q43971441 |
| | Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics | Q44239783 |
| | Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis | Q44691029 |
| | Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study | Q44790762 |
| | Cannabis use and psychosis: a longitudinal population-based study. | Q44820509 |
| | A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission | Q44853701 |
| | Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder | Q44915184 |
| P921 | main subject | schizophrenia | Q41112 |
| | psychosis | Q170082 |
| P304 | page(s) | 1 | |
| P577 | publication date | 2011-01-17 | |
| P1433 | published in | Frontiers in Behavioral Neuroscience | Q21971195 |
| P1476 | title | Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light | |
| P478 | volume | 5 | |